Patents Assigned to Merck Patents GmbH
  • Publication number: 20170117477
    Abstract: The invention relates to novel organic semiconducting compounds, which are small molecules or conjugated polymers, containing one or more fluorinated polycyclic units, to methods for their preparation and educts or intermediates used therein, to compositions, polymer blends and formulations containing them, to the use of the compounds, compositions and polymer blends as organic semiconductors in, or for the preparation of, organic electronic (OE) devices, especially organic photovoltaic (OPV) devices, organic photodetectors (OPD), organic field effect transistors (OFET) and organic light emitting diodes (OLED), and to OE, OPV, OPD, OFET and OLED devices comprising these compounds, compositions or polymer blends.
    Type: Application
    Filed: March 17, 2015
    Publication date: April 27, 2017
    Applicant: Merck Patent GmbH
    Inventors: Mansoor D'LAVARI, William MITCHELL, Changsheng WANG, David SPARROWE
  • Publication number: 20170115439
    Abstract: The present invention relates to a polarized light emissive device comprising a plural of fluorescent semiconductor quantum rods, and to a preparation thereof. The invention further relates to a use of the polarized light emissive device in optical devices, and to an optical device comprising the polarized light emissive device.
    Type: Application
    Filed: March 6, 2015
    Publication date: April 27, 2017
    Applicant: Merck Patent GmbH
    Inventor: Masaki HASEGAWA
  • Patent number: 9634268
    Abstract: Electronic devices, in particular organic electroluminescent devices, comprising metal complexes of the formula (1).
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: April 25, 2017
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Dominik Joosten, Esther Breuning
  • Publication number: 20170107426
    Abstract: The invention relates to europium or samarium-doped terbium molybdates, to a method for producing said compounds, and to the use of the claimed europium or samarium-doped terbium molybdates as conversion lumiophores. The invention also relates to a light-emitting device containing a claimed europium or samarium-doped terbium molybdate.
    Type: Application
    Filed: February 17, 2015
    Publication date: April 20, 2017
    Applicant: MERCK PATENT GMBH
    Inventors: Ralf PETRY, Thomas JUESTEL, Florian BAUR
  • Publication number: 20170107379
    Abstract: Frits or frit mixtures with pearlescent pigments for materials, such as ceramic glazes, which are stable above 1000° C.
    Type: Application
    Filed: September 30, 2016
    Publication date: April 20, 2017
    Applicant: MERCK PATENT GMBH
    Inventors: Lukas HAMM, Carsten HANDROSCH, Nicole NELISCHER
  • Publication number: 20170105915
    Abstract: The present invention relates to ?-Al2O3 flakes prepared by a process comprising (1) preparation of an aqueous solution of at least one water-soluble and/or insoluble aluminum salt which optionally contains at least one sulfate compound, (2) adding a basic solution and optionally at least one dopant to the aluminum salt solution (1), (3) drying of the obtained gel, followed by calcination to obtain Al2 03 flakes and alkali salts in a molten salt, and (4) removal of the water soluble parts of the calcined molten salt obtained in step (3).
    Type: Application
    Filed: May 4, 2015
    Publication date: April 20, 2017
    Applicant: Merck Patent GmbH
    Inventors: Ryuta SUZUKI, Yukitaka WATANABE, Sabine SCHOEN, Noriyuki MATSUDA
  • Publication number: 20170107222
    Abstract: The invention provides novel substituted pyridyl piperidine compounds according to Formula (I) which are Wnt pathway inhibitors, their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.
    Type: Application
    Filed: March 10, 2015
    Publication date: April 20, 2017
    Applicants: MERCK PATENT GMBH, Cancer Research Technology Limited
    Inventors: Kai SCHIEMANN, Frank STIEBER, Michel CALDERINI, Julian BLAGG, Aurelie MALLINGER, Dennis WAALBOER, Christian RINK, Simon Ross CRUMPLER
  • Patent number: 9624246
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: April 18, 2017
    Assignee: Merck Patent GmbH
    Inventors: Xiaoling Chen, Ruoxi Lan, Catherine Jorand-Lebrun, Henry Yu, Andreas Goutopoulos
  • Patent number: 9624298
    Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: April 18, 2017
    Assignee: Merck Patent GmbH
    Inventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
  • Patent number: 9627626
    Abstract: The present invention relates to aromatic nitrogen heterocycles, and to electronic devices, in particular organic electroluminescent devices, which comprise these aromatic nitrogen heterocycles, in particular in a hole-injection layer and/or in a hole-transport layer and/or in a hole-blocking layer and/or in an electron-transport layer and/or in an emitting layer.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: April 18, 2017
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Arne Buesing, Esther Breuning, Christof Pflumm, Amir Hossain, Thomas Eberle, Teresa Mujica-Fernaud
  • Patent number: 9624264
    Abstract: The present invention relates to compounds of the formula (I) and in particular to medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries arthritis, pain, allodynia or hyperalgesia.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: April 18, 2017
    Assignee: Merck Patent GmbH
    Inventors: Christos Tsaklakidis, Markus Klein
  • Patent number: 9627632
    Abstract: An uncharged compound of the formula (1) M(L)n(L?)m(L?)o??Formula (1) containing a substructure M(L)n of the formula (3) or (4) M is a transition metal; E is identical or different on each occurrence and is in each case a sp2-hybridized carbon or nitrogen atom; Z is identical or different on each occurrence and is in each case C(R)2 or NR; Cy1 and Cy2 are identical or different on each occurrence and are in each case a substituted or unsubstituted heterocycle which coordinates to M via the N atom and may have a bond to the group Z. The compound can also be used in an oligomer, polymer, dendrimer or an electronic component.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: April 18, 2017
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Hermann Mayer, William Kaska
  • Publication number: 20170101523
    Abstract: The present invention relates to laser-markable and laser-weldable polymeric materials which are distinguished by the fact that they comprise at least one fluorine-doped tin oxide (FTO) as absorber.
    Type: Application
    Filed: May 22, 2015
    Publication date: April 13, 2017
    Applicant: Merck Patent GmbH
    Inventors: Reinhold RUEGER, Ulrich QUITTMANN
  • Patent number: 9617266
    Abstract: Compounds of the formula I in which X, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: April 11, 2017
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Dieter Dorsch, Ansgar Wegener, Oliver Poeschke, Michael Busch, Jeyaprakashnarayanan Seenisamy
  • Patent number: 9620722
    Abstract: The present invention relates to compounds of the formula (1) and formula (2), which are suitable for use in electronic devices, in particular in organic electroluminescent devices.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: April 11, 2017
    Assignee: Merck Patent GmbH
    Inventors: Irina Martynova, Christof Pflumm, Amir Hossain Parham, Rémi Manouk Anémian, Teresa Mujica-Fernaud, Claire De Nonancourt
  • Patent number: 9617349
    Abstract: The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: April 11, 2017
    Assignee: Merck Patent GmbH
    Inventor: Stephen D. Gillies
  • Patent number: 9617473
    Abstract: The present invention relates to a switch element, which is thermoresponsive and which switches between a less transmissive state for radiant energy and a more transmissive state for radiant energy, and which comprises a liquid-crystalline medium. The invention furthermore relates to the use of the switch element for the regulation of radiant energy flow between interior spaces and the environment and for the regulation of the temperature of interior spaces. The invention furthermore relates to a liquid-crystalline medium, characterised in that it comprises 5-95% of a compound of the formula (I), in particular for use in the switch elements according to the invention.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: April 11, 2017
    Assignee: Merck Patent GmbH
    Inventor: Michael Junge
  • Patent number: 9620716
    Abstract: The invention relates to novel organic semiconducting polymers containing one or more monomers derived from s-indacene fused symmetrically on each terminus with dithieno[3,2-b;2?,3?-d]thiophene (IDDTT), cyclopenta[2,1-b;3,4-b?]dithiophene (IDCDT), or derivatives thereof, to methods for their preparation and educts or intermediates used therein, to polymer blends, mixtures and formulations containing them, to the use of the polymers, polymer blends, mixtures and formulations as semiconductors in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising these polymers, polymer blends, mixtures or formulations.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: April 11, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Changsheng Wang, William Mitchell, Nicolas Blouin, Jingyao Song, Mansoor D'Lavari, Steven Tierney
  • Patent number: 9617171
    Abstract: A biocidal purification reactor, including a main cylinder tube (1A;1B), at least one end cap (2A,2B,2C) closing at least one axial end opening of the main cylinder tube (1A;1B), at least two ports (3A,3B) communicating with the interior volume (4) of the main cylinder tube (1A;1B) in the vicinity of the respective axial ends of the cylinder tube (1A;1B), and at least one of said end caps (2A) or said main cylinder tube (1B) including a UV-light source (7A;7B).
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: April 11, 2017
    Assignee: Merck Patent GmbH
    Inventors: Pascal Rajagopalan, Julien Gross, Ichiro Kano, Yves Gaignet
  • Patent number: 9611428
    Abstract: The invention relates to an electro-optical liquid-crystal display having a re-alignment layer for the re-alignment of the liquid crystals whose field has a component, crucial for the re-alignment, parallel to the liquid-crystal layer, containing a liquid-crystalline medium, characterized in that it contains at least one compound of the formula (I), at least one compound of the formula (II), and at least one compound of the formula (III), in which the parameters R11 to R31, X11 and X21 have the meanings indicated in Claim 1.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: April 4, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Markus Czanta, Harald Hirschmann, Izumi Saito, Volker Reiffenrath, Lars Lietzau